abstract: UNASSIGNED: 2557 Background: @entity3118 -based therapies prolong survival of @entity1 (pts) with @entity1072 ( @entity1072 ), but deplete @entity404 T-cells causing immunosuppression which increases the risk of @entity281 and may limit control of minimal @entity66 by the immune system. Adoptive immunotherapy using autologous CD3/ @entity1361 -costimulated T-cells expanded ex vivo (ACTC) enhances immune reconstitution after @entity3118 -based therapy of @entity706 (Schuster Blood abstract 2007). METHODS: We conducted a multicenter phase I/II trial of ACTC following @entity3118 -based therapy of @entity1072 . After leukapheresis, pts received @entity3118 -based therapy. 8 - 12 weeks after last chemotherapy, responding pts (CR, @entity19485 , PR) received a single dose of ACTC prepared from autologous T-cells collected before chemotherapy. RESULTS: 34 pts are enrolled (median age 62). To date, 13 pts are evaluable for studies of immune reconstitution at >90 days after ACTC. Prior to ACTC, 8 pts received FCR and 1 pt FR as first therapy, while 3 pts received FCR and 1 pt FCR + bevacizumab for previously treated @entity1072 . Median ACTC dose was 6.81E+09 CD3 cells (range: 4.15E+08 - 1.05E+10). After chemotherapy prior to ACTC (d0), median @entity404 count was 116 (range: 12-173); 90 days after ACTC (d90), median @entity404 count was 384 (range 62-963) (p = 0.006; median fold @entity404 increase 3.2, range 0.5 - 10.5). In contrast, median @entity405 count did not change significantly (median: d0 = 79, range: 4-682; d90 = 257, range: 18-514). The increase in @entity404 count between day 0 and day 90 was not dependent on ACTC dose. In 5/6 pts studied, significantly enhanced T-cell immunosynapse formation with autologous @entity1072 (assay, Ramsay JCI 2008) was demonstrated by comparing percent synapse formation in post-ACTC product and pre-treatment peripheral blood T-cells (p < 0.005). There were no SAEs; 1 pt developed AIHA after ACTC. For 13 evaluable pts, at a median follow-up of 185 days (range: 92 - 497), PFS from ACTC is 91%. CONCLUSIONS: ACTC results in a dose-independent acceleration of @entity404 + cell recovery after @entity3118 -based chemotherapy compared to historical controls. Further studies of immune reconstitution following ACTC are in progress.

title: Adoptive immunotherapy with autologous CD3/ @entity1361 -costimulated T cells after XXXX -based chemotherapy in @entity1 with @entity1072 .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine', 'fludarabine']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity3118 :: (MESH:C024352,Chemical) :: ['fludarabine']


abstract: Improved health may extend or shorten the duration of @entity73 by postponing incidence or @entity204 . We assess the duration of @entity73 in the US Health and Retirement Study (1992-2004) by self reported BMI, smoking and levels of education in @entity1 and @entity1 and three ethnic groups. We define multistate life tables by the transition rates to @entity73 , recovery and @entity204 and estimate @entity797 proportional hazard ratios for the studied determinants. 95% confidence intervals are obtained by bootstrapping. 55 year old white @entity1 and @entity1 expect to live 25.4 and 30.0 years, of which 1.7 [95% confidence intervals 1.5; 1.9] years and 2.7 [2.4; 2.9] years with @entity73 . Both black @entity1 and @entity1 live 3.7 [2.9; 4.5] years longer with @entity73 than whites, Hispanic @entity1 and @entity1 3.2 [1.9; 4.6] and 5.8 [4.2; 7.5] years. BMI makes no difference. Smoking decreases the duration of @entity73 with 0.8 [0.4; 1.3] years by high mortality. Highly educated @entity1 and @entity1 live longer, but 1.6 years [1.1; 2.2] and 1.9 years [1.6; 2.6] shorter with @entity73 than lowly educated @entity1 and @entity1 . The effect of education is more pronounced among ethnic minorities. Higher life expectancy goes together with a longer period of @entity73 , but not for higher levels of education: that extends life in good cognitive health but shortens the period of @entity73 . The increased duration of @entity73 in minority ethnic groups needs further study, also in Europe.

title: Higher education delays and shortens XXXX : a multistate life table analysis of the US Health and Retirement Study.

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment']

answer: @entity73 :: (MESH:D003072,Disease) :: ['cognitive impairment']


abstract: Deficient cellular cytotoxic mechanisms are present in neonates, contributing to their increased susceptibility to certain viruses, notably herpes simplex virus (HSV). Significant lymphokine-activated killer (LAK) cell activity has been described in cord blood, suggesting a possible role for LAK and/or @entity1199 ( @entity1199 ) therapy in newborns with serious @entity1800 . The effect of HSV (type 1) on the activation of cord versus adult LAK cells was investigated by adding virus (multiplicity of @entity281 , MOI = 10) to cells that had been previously incubated for 4-6 days with @entity1199 (50-100 U/ml). The cells were then tested 24 h after virus exposure for cytotoxic activity against 51Cr-labelled K562 and Raji target cells. HSV inhibited @entity137 of adult cells against K562 by 44% (72 +/- 2.4%, SEM; specific lysis to 40 +/- 6.2%, n = 15) and by 62% against Raji targets (50 +/- 5.6 to 19 +/- 4.4%). A similar degree of inhibition was observed for cord cells against K562 (76 +/- 2.0 to 46 +/- 5.3%) and Raji (60 +/- 4.6 to 24 +/- 6.2%). The degree of inhibition was correlated with the dose of virus in dose-response experiments. Inhibition was also noted with irradiated (10,000 rad) but not with heat-inactivated (56 degrees C for 60 min) virus. No inhibition was found when virus was added directly to the cytotoxic assay or when virus was added at the initiation or end of culture of cells with @entity1199 (i.e. day 0 or day 5-7). In contrast, HSV stimulated cytotoxic activity against both the natural killer (NK)-sensitive (K562) and NK-resistant (Raji) targets in cells not incubated with @entity1199 . The @entity137 of adult cells incubated with infectious HSV (MOI = 10) for 5-7 days increased from 5.5 +/- 1.9% in the absence of virus to 25 +/- 6.0% against K562 in the presence of virus and from 3.5 +/- 1.0 (no virus) to 16 +/- 4.3% (with virus) against Raji targets (n = 8). The @entity137 of cord cells was also stimulated, but to a lesser degree. Irradiated virus also stimulated cytotoxic activity but to a lesser degree in cord cells. Virus-induced nonspecific @entity137 may represent an important component of the host's antiviral defense that is present at birth, but somewhat diminished compared to normal adults.

title: Effects of herpes simplex virus on induced cell-mediated XXXX in neonates and adults.

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral infections']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['LAK cytotoxicity', 'cytotoxicity']

answer: @entity137 :: (MESH:D064420,Disease) :: ['cytotoxicity']


abstract: BACKGROUND: Classic KS (CKS) mainly affects elderly @entity1 , has an irregular course, and is relatively benign for years. However, sometimes the disease may progress rapidly and spread to internal organs, thus necessitating systemic chemotherapy. We therefore decided to carry out a prospective trial using @entity5713 and @entity1732 , which are active, easy to administer and control, and low cost. METHODS: We treated 29 @entity1 affected by CKS with @entity5713 i.v., up to 10 mg in combination with @entity1732 i.m., 15 IU every 3 weeks. We administered a median of seven cycles of therapy. RESULTS: All the 29 enrolled @entity1 were evaluated: 21% reached a complete response and 76% had an intermediate response. @entity137 was limited. The maximal response was attained in a median of 5 months, with a mean duration of 4 months. CONCLUSION: The combination of @entity5713 and @entity1732 achieved a high rate of objective responses in a subgroup of elderly and symptomatic @entity1 , without considerable @entity137 . We recommend the combination as first line chemotherapy for advanced CKS.

title: Combination of @entity5713 and XXXX as first line therapy in advanced classic Kaposi's sarcoma.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']

answer: @entity1732 :: (MESH:D001761,Chemical) :: ['bleomycin']


abstract: Extracellular matrix is the gold standard for tissue regeneration. In this study, we directly made the extracellular matrix of the tissue or organ into scaffold for @entity1566 , a strategy that is seldomly tried in spinal cord engineering. The aim of this study was to determine if the chemically extracted acellular muscle could be a potential scaffold for @entity1566 . The chemically extracted acellular muscle was implanted in the lateral hemisected adult @entity35 thoracic spinal cord. Control @entity35 were similarly injured. After 1 and 4 weeks, scaffold integration and biocompatibility, axon sprouting, and myelination were evaluated. The chemically extracted acellular muscle scaffolds were found to be well integrated with the host tissue. Sprouting axons grew into the full length of the scaffold in a strikingly parallel and linear fashion. A few remyelinated axons were also detected in the scaffolds. The tracing results in another six @entity35 showed that labeled fibers entered the chemically treated muscle grafts. Furthermore, there were no apparent quantitative differences in the ED-1 and glial fibrillary acidic protein positive cells between groups. Neuron counting showed more surviving neurons in the acellular muscle treated group than those of the injured only group. Vascularization of the grafts was also confirmed. These findings clearly demonstrated that chemically extracted acellular muscle grafts provided useful biomatrices to enhance axon sprouting in the injured spinal cord.

title: Chemically extracted acellular muscle: a new potential scaffold for XXXX repair.

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'spinal cord injuries']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: PSD-93/chapsin-110 is a neuronal PDZ domain-containing protein that binds to and clusters the @entity1024 receptor (NMDAR) at synapses in the central nervous system. It also assembles a specific set of signaling proteins around the NMDAR and mediates downstream signaling by the NMDAR. Thus, PSD-93/chapsin-110 might be involved in many physiological and pathophysiological actions triggered via the activation of the NMDAR. In the current study, we report that abundant PSD-93/chapsin-110 protein was detected in @entity35 spinal cord, particularly in the superficial dorsal horn. The @entity35 injected intrathecally with PSD-93/chapsin-110 antisense oligodeoxynucleotide every 24 h for 4 days displayed not only a remarkable decrease in spinal cord PSD-93/chapsin-110 expression but also a significant reduction in the paw withdrawal responses to thermal and mechanical stimuli during complete Freund's adjuvant-induced @entity158 and @entity1897 -induced @entity9 . In contrast, the @entity35 injected intrathecally with PSD-93/chapsin-110 missense oligodeoxynucleotide did not exhibit these changes. We also found that pretreatment with PSD-93/chapsin-110 antisense oligodeoxynucleotide did not change the locomotor activity or the responses to acute noxious thermal and mechanical stimuli in intact @entity35 . The present results indicate that the deficiency of spinal cord PSD-93/chapsin-110 protein significantly attenuates thermal and mechanical @entity1931 in complete Freund's adjuvant- or @entity1897 -induced @entity1118 . This suggests that spinal cord PSD-93/chapsin-110 might be involved in the central mechanism of @entity1118 . Our work might provide a new target for the therapy of @entity1118 .

title: Effect of knock down of spinal cord PSD-93/chapsin-110 on persistent @entity158 induced by complete Freund's adjuvant and XXXX .

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate']

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral nerve injury']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['inflammatory pain']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

answer: @entity1897 :: (MESH:D010523,Disease) :: ['peripheral nerve injury']


abstract: Selection for contextual fear conditioning is an important behavioral paradigm for studying the role of genetic variables and their interaction with the surrounding environment in the etiology and development of @entity148 . Recently, a new line of animals selectively bred for high levels of freezing in response to contextual cues previously associated with footshock was developed from a @entity35 population. The purpose of the present study was to evaluate the emotional and cognitive aspects of this new line of animals, which has been named @entity2101 ( @entity2101 ). For the characterization of @entity146 , @entity2101 and control animals were tested in the elevated plus-maze (EPM) and the social interaction test. @entity2101 animals were significantly more anxious than control @entity35 in terms of both the number of entries into EPM open arms and the percentage of time spent in these arms. The time spent in social interaction behavior was also significantly decreased. No statistical differences were found in locomotor activity, as measured by both the number of entries into the closed arms of the EPM and the number of crossings into the social interaction test arena. No differences between @entity2101 and control groups were found in the @entity308 forced swimming test, suggesting that the anxiety trait selected in the @entity2101 line did not interact with affective disorders traits such as those for @entity308 . Cognitive aspects of the @entity2101 @entity35 were evaluated in the object recognition task. Results from this test indicated no difference between the two groups. The present study also encompassed histological analysis of the dorsal hippocampus from @entity2101 and control animals. Results revealed an absence of qualitative and quantitative differences between these two groups of animals in cells located in the dentate gyrus, @entity1249 , and @entity1251 areas. Therefore, future studies are required to further investigate the possible neural mechanisms involved in the origin and development of the anxious phenotype observed in this model.

title: Behavioral profile and dorsal hippocampal cells in carioca high-conditioned freezing XXXX .

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['anxious behavior']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety disorders']

entities_list: @entity2101 :: ('MESH:C538394', 'Disease') :: ['Carioca High-Freezing', 'CHF']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: The development and clinical evaluation of a LightCycler PCR assay, including an internal process control (IPC), to detect the @entity328 autolysin gene in clinical samples is reported. The assay was developed to provide a second target for use in conjunction with existing pneumolysin PCR assays to increase the reliability of non-culture PCR diagnosis of @entity7706 . Primers amplify a 173 bp fragment of the autolysin gene (lytA), which is detected by fluorescence-labelled hybridization probes. An IPC was designed to check for the presence of PCR inhibitors and loss of assay sensitivity. The IPC product was amplified by the lytA primers and detected by a second set of hybridization probes. The analytical specificity of the autolysin PCR assay was 100% against 39 other bacterial species tested; these included related streptococci and other organisms. The assay, which could reliably detect 50 fg purified pneumococcal DNA per reaction, was capable of distinguishing between @entity2260 and atypical @entity6419 and @entity9858 strains known to contain the lytA gene. Using DNA extracts from a panel of @entity1098 bloods from @entity1 with blood-culture-confirmed @entity7706 , the autolysin PCR had a sensitivity of 42.9%, which was similar to a previously reported TaqMan pneumolysin PCR (43.8%) run in parallel. Total agreement was shown between the autolysin assay and the pneumolysin TaqMan assay when used to test 23 culture-negative clinical samples, of which eight were positive by PCR, adding valuable clinical information. A specific autolysin-based LightCycler assay has been developed to complement pneumolysin PCR for the detection of @entity2260 in clinical samples. This should be a particularly useful tool for the rapid and sensitive diagnosis of @entity2506 , even after an antibiotic has been administered. However, poor sensitivity on blood samples limits its usefulness in other @entity281 .

title: Autolysin-targeted LightCycler assay including internal process control for detection of XXXX DNA in clinical samples.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity9858 :: ('1303', 'Species') :: ['Streptococcus oralis']

entities_list: @entity7706 :: ('MESH:D011008', 'Disease') :: ['pneumococcal infection']

entities_list: @entity6419 :: ('28037', 'Species') :: ['Streptococcus mitis']

entities_list: @entity2506 :: ('MESH:D008586', 'Disease') :: ['pneumococcal meningitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['bacteraemic infections']

entities_list: @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae']

answer: @entity328 :: (1313,Species) :: ['Streptococcus pneumoniae']


abstract: The @entity2491 protein @entity669 phosphatase SptP is a target of the centisome 63 type III protein secrtion system. This system is essential for the interaction of these bacteria with host cells. We have shown here by a combination of biochemical and microscopy techniques that @entity2491 directs the translocation of SptP into cultured epithelial cells. Translocation requires the function of the secreted proteins, SipB, SipC and SipD, as strains carrying mutations in any of the genes encoding these proteins fail to translocate SptP. Microinjection of purified GST-SptP into cultured cells results in the disruption of the actin cytoskeleton and the disappearance of stress fibres. These changes are reversible, as microinjected cells regain the normal appearance of their actin cytoskeleton upon prolonged incubation. Microinjection of the catalytically active GST-SptP( @entity59134 ) protein results in changes similar to those induced by the wild-type toxin. Furthermore, microinjection of a fusion protein between GST and the first 285 @entity1522 of SptP also leads to identical disruption of the host cell actin cytoskeleton, indicating that the @entity1472 -terminal half of SptP is sufficient to mediate this effect. However, microinjection of a fusion protein between GST and the last 259 @entity1522 of SptP also disrupted the normal appearance of the cytoskeleton. These results support the hypothesis that SptP is an effector protein arranged in modular domains that may co-operate with each other to exert relate functions.

title: The XXXX @entity669 phosphatase SptP is translocated into host cells and disrupts the actin cytoskeleton.

entities_list: @entity2491 :: ('90371', 'Species') :: ['Salmonella typhimurium', 'S. typhimurium']

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity2491 :: (90371,Species) :: ['Salmonella typhimurium']


abstract: BACKGROUND: Although it is assumed that @entity28 @entity1 are naturally protected against anterior @entity2980 , the relationship has never been formally studied. We sought to examine the impact of body mass index (BMI) on severity of @entity130 , need for operation, and @entity1 outcomes. MATERIALS AND METHODS: We conducted a review of all @entity1 presenting with @entity2980 at an urban level I @entity130 center from January 2000-December 2012. @entity1 were divided into groups based on their BMI (<18.5, 18.5-29.9, 30-35, and >35). Data abstracted included baseline demographics, physiologic data, and characterization of whether the stab wound had violated the peritoneum, caused @entity3511 , or required an operation that was therapeutic. The one-sided Cochran-Armitage trend test was used for significance testing of the protective effect. RESULTS: Of 281 @entity1 with @entity2980 , 249 had complete data for evaluation. Chest and @entity130 scale trends decreased with increasing BMI, as did overall injury severity score, the percent of @entity1 severely injured (injury severity score >= 25), and length of intensive care unit stay. Rates of peritoneal violation (100%, 84%, 77%, and 74%; P  =  0.077), @entity130 (83%, 56%, 50%, and 30%; P  =  0.022), and injury requiring a therapeutic operation (67%, 45%, 40%, and 20%; P  =  0.034) all decreased with increasing BMI. @entity1 in the thinnest group required an operation three times more often than those in the most @entity28 . CONCLUSIONS: Increased BMI protects @entity1 with @entity2980 and is associated with lower incidence of severe injury and need for operation. Heavier @entity1 may be more suitable to observation and serial examinations, whereas very thin @entity1 are more likely to require an operation and be critically injured.

title: Impact of body mass index on XXXX : implications for management.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity2980 :: ('MESH:D014951', 'Disease') :: ['abdominal stab wounds']

entities_list: @entity3511 :: ('MESH:D000007', 'Disease') :: ['intra-abdominal injury']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['sustained injury', 'visceral injury', 'abdomen abbreviated injury', 'trauma']

answer: @entity3511 :: (MESH:D000007,Disease) :: ['injury in abdominal stab wounds']


abstract: BACKGROUND: The safety and efficacy of yttrium 90 ((90) Y) therapy for unresectable infiltrative @entity157 ( @entity157 ) with @entity715 ( @entity715 ) requires further evaluation. METHODS: A prospective, single-center safety and feasibility study recruited @entity1 with unresectable (Barcelona Clinic @entity96 stage C) infiltrative @entity157 with @entity715 . Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0. @entity1349 ( @entity1349 ) and @entity1054 ( @entity1054 ) were measured from the first (90) Y therapy. Survival analysis was performed with Kaplan-Meier estimation. Prognostic factors were tested with a log-rank test and Cox proportional regression analysis. RESULTS: Overall, 45 @entity1 were recruited, and 30 @entity1 who met the study's inclusion criteria underwent glass-based (90) Y therapy. Four @entity1 (13%) had transient @entity137 (grade   >=    2). Ten @entity1 (33%) had related emergency department visits, with 5 @entity1 (17%) requiring short-term hospitalization. No radiation @entity55 , gastrointestinal @entity1066 , or procedure-related mortality occurred. The median @entity1349 was 13 months (95% confidence interval, 4.4-22 months) with a @entity1054 of 9 months (95% confidence interval, 6.2-13.1 months). Absence of @entity843 , an international normalized ratio   <   1.2, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, @entity1 -Pugh class A, a macroaggregated albumin lung shunt fraction (LSF)   <   10%, and no @entity137 were significant predictors of prolonged @entity1349 according to a univariate analysis (P   <   .05). A multivariate analysis found an ECOG performance status of 0, @entity1 -Pugh class A, an LSF   <   10%, and lack of transient @entity137 (grade   >=    2) to be independent predictors of prolonged @entity1349 (P   <   .05). An ECOG performance status of 0, @entity1 -Pugh class A, and an LSF   <   10% were also predictors of prolonged @entity1054 according to the multivariate analysis (P   <   .05). CONCLUSIONS: In @entity1 with unresectable infiltrative @entity157 and @entity715 , (90) Y therapy appears to be a safe and viable therapy. @entity5 2015.    2015 American @entity5 Society.

title: Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative @entity157 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['hepatobiliary toxicity']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['Liver Cancer']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulceration']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['portal vein thrombosis', 'PVT']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']

answer: @entity715 :: (MESH:D013927,Disease) :: ['portal vein thrombosis']


abstract: The introduction deals with of the history, etiology and, briefly, clinical manifestations of endemic @entity8 . The authors state that a large number of investigations have been done until today, but without producing a diagnostic test for early diagnosis of the disease. This led the authors to pursue certain laboratory investigations. The control group consisted of 30 healthy individuals while @entity1 diagnosed as Endemic @entity8 were grouped according to stages of the disease: initial, developed, terminal stages. Nucleotides in erythrocytes (5' UMP, @entity18828 , @entity37084 , 5,CMP, @entity1920 , 5' @entity857 , 5' @entity855 ) were determined on the Acidic Aminoanalyzer, with use of a special UV detector. @entity2661 in the urine were determined by using ratiofluorometery. @entity1011 phosphocinase, hydroxybutirat--dehydrogenase and 2,3 DPG were determined on the "Carlbiochem" enzymometer. LDH, its isoenzymes as well as its profile were determined by electrophoresis on starch gel. Specific proteins such as haptoglobin, alpha 2 macroglobulin, alpha 1 antitrypsin, alpha 1 acid glycoprotein, properdin factor B, ceruloplasmin were determined on the Immunochemistry Analyzer. Total @entity165 and @entity165 in lipoproteins fractions VLDL, LDL and HDL were determined on the @entity165 Analyzer. All results were evaluated statistically. Our conclusion is that they are interesting and contribute to the diagnosis of endemic @entity8 .

title: [Levels of immunoglobulins in various media from healthy pregnant XXXX and @entity1 with diabetes mellitus and EPH gestosis].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy', 'Nephropathy']

entities_list: @entity2661 :: ('MESH:D002395', 'Chemical') :: ['Catecholamines']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol', 'cholesterol']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['Creatinine']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: The results of @entity174 fixation using metal wire and non-absorbable @entity2635 (5 Ethibond) are presented. In group 1 (21 cases), the standard "AO" technique using stainless steel wire was used, and in group 2 (16 cases) we used 5 Ethibond. @entity1 were assigned to the two groups on surgeon preference. Post-operative management in the two groups was similar, with @entity1 being allowed to mobilise as comfort allowed, under the supervision of the physiotherapists. All @entity1 were followed-up until union of the @entity174 or until further surgical intervention was carried out. At a mean of 2 years and 6 months (range 1-4 years), we reviewed the notes and X-rays of all 37 cases. In group 2 there were no cases of @entity281 but there were three cases of post-operative infections in group 1. Re-operation rate was 6/21 (38%) in group 1 and 1/6 (6%) in group 2. Therefore, the relative risk of re-operation in the metal group is six times that in the non-absorbable @entity2635 group. The risk of @entity281 in the metal group is also higher. These have implication on @entity1 morbidity associated with the operative treatment of @entity174 . Non-absorbable @entity2635 appears to compare favourably with the use of metallic wire to fix @entity174 .

title: Clinical experience of XXXX fixation using metal wire or non-absorbable @entity2635 --a study of 37 cases.

entities_list: @entity2635 :: ('CHEBI:60160', 'Chemical') :: ['polyester']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'patellar fractures', 'patellar fracture']

answer: @entity174 :: (MESH:D050723,Disease) :: ['patellar fracture']


abstract: A nihilistic approach to the treatment of @entity1 with medically inoperable, early stage @entity1149 ( @entity1149 ) is not warranted. Despite the frequency of comorbid medical illness in @entity1 with medically inoperable @entity1149 , @entity2 progression is the major cause of morbidity and @entity204 . Although expectations for cure are reduced compared to good-risk @entity1 (eg, adequate pulmonary reserve), modest long-term survival rates of @entity1 have been reported, after definitive therapy. A comparison of radiotherapy and limited resection is difficult because of the lack of randomized data and the selection bias inherent in retrospective reports. For example, @entity1 treated with surgery have peripheral lesions, undergoing @entity5 compared to @entity1 treated with radiotherapy. In a multidisciplinary thoracic program, @entity1 are counseled on the options of sublobar resection and conformal radiotherapy. The efficacy of adjuvant radiotherapy, after limited resection, in reducing local recurrence in @entity1 with medically inoperable @entity1149 is unclear. However, adjuvant radiotherapy may be considered if a postoperative target volume can be defined, particularly if resection margins are narrow. Considering the benefit of chemoradiotherapy for @entity1 with locally advanced disease, combination therapy is administered to @entity1 with good performance status and large (eg, > 4 cm) primary lesions, although combined therapy may increase the potential for @entity358 in @entity1 with baseline @entity358 . Prospective data are becoming available to define the value of treatment alternatives for @entity1 with medically inoperable @entity1149 . The @entity5 and @entity1778 Group B completed a phase II study of thoracoscopic wedge resection and postoperative radiotherapy, whereas a phase I trial of dose-intensive accelerated conformal radiotherapy is ongoing. Trials involving systemic therapy for @entity1 with medically inoperable @entity1149 should be developed.

title: Early stage medically inoperable XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rigorous staging', 'Cancer']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity', 'pulmonary dysfunction']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: Laparoscopic appendectomy has been widely practiced for @entity698 ; various reports demonstrated its merits in assisting diagnosis, reducing @entity282 , analgesic requirement, and incidence of @entity2737 . The role of laparoscopy in management of @entity532 , ie, gangrenous, @entity698 and @entity2466 , remains undefined. Currently, the choice of operative approach is mostly at the surgeons' discretion. A retrospective study was conducted in our institution to review the feasibility, safety, and efficacy of laparoscopic appendectomy for @entity1 with @entity532 . STUDY DESIGN: From January 1999 to January 2004, records of @entity1 older than 14 years of age with diagnosis of @entity698 were retrieved from computer database for analysis. All @entity1 underwent diagnostic laparoscopy to confirm diagnosis of @entity532 , and @entity1 subsequently underwent either laparoscopic or open appendectomies. @entity1 ' demographics data and perioperative outcomes from the two groups were compared. RESULTS: During the study period, 1,133 @entity1 with @entity697 underwent operations in our institution. Two hundred forty-four @entity1 (21.5%) with @entity532 were identified by laparoscopy, of which 175 underwent laparoscopic appendectomy (LA) and 69 had @entity1538 ( @entity1538 ). Both groups of @entity1 were comparable in demographics. Mean operative time was 55 minutes for LA group and 70 minutes for the @entity1538 group (p<0.001). Mean hospital stay was 5 days and 6 days for LA and @entity1538 group respectively (p<0.001). There was one conversion @entity1 (0.6%) in the LA group who suffered from @entity2737 , and there were seven (10%) wound @entity281 in the @entity1538 group (p=0.001). There were 10 cases (5.7%) of intraabdominal collection in the LA group and 3 (4.3%) in the @entity1538 group (p=0.473). There was no mortality in the current series. CONCLUSIONS: Laparoscopic appendectomy for @entity532 is feasible and safe. It is associated with a significantly shorter operative time, lower incidence of @entity2737 , and reduced length of hospital stay when compared with @entity1 who had @entity1538 .

title: Laparoscopic versus XXXX for @entity532 .

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute appendicitis']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open appendectomy', 'OA']

entities_list: @entity698 :: ('MESH:D001064', 'Disease') :: ['perforated appendicitis', 'uncomplicated appendicitis', 'appendicitis']

entities_list: @entity2466 :: ('MESH:D001063', 'Disease') :: ['appendiceal abscess']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['complicated appendicitis']

entities_list: @entity2737 :: ('MESH:D014946', 'Disease') :: ['wound infection']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

answer: @entity1538 :: (MESH:D005902,Disease) :: ['open appendectomy']


abstract: BACKGROUND: Current intra-domiciliary vector control depends on the application of residual insecticides and/or repellents. Although biological control agents have been developed against aquatic mosquito stages, none are available for adults. Following successful use of an entomopathogenic fungus against tsetse flies (Diptera: Glossinidae) we investigated the potency of this fungus as a biological control agent for adult @entity311 and @entity6565 vector mosquitoes. METHODS: In the laboratory, both sexes of @entity313 and @entity2957 were passively contaminated with dry conidia of @entity20703 . Pathogenicity of this fungus for An. gambiae was further tested for varying exposure times and different doses of oil-formulated conidia. RESULTS: Comparison of Gompertz survival curves and LT50 values for treated and untreated specimens showed that, for both species, infected mosquitoes died significantly earlier (p < 0.0001) than uninfected control groups. No differences in LT50 values were found for different exposure times (24, 48 hrs or continuous exposure) of An. gambiae to dry conidia. Exposure to oil-formulated conidia (doses ranging from 1.6 x 10(7) to 1.6 x 10(10) conidia/m2) gave LT50 values of 9.69 +/- 1.24 (lowest dose) to 5.89 +/- 0.35 days (highest dose), with @entity281 percentages ranging from 4.4-83.7%. CONCLUSION: Our study marks the first to use an entomopathogenic fungus against adult Afrotropical disease vectors. Given its high pathogenicity for both adult Anopheles and Culex mosquitoes we recommend development of novel targeted indoor application methods for the control of endophagic host-seeking females.

title: Infection of @entity311 ( XXXX s.s.) and @entity6565 ( @entity2957 ) vectors with the entomopathogenic fungus @entity20703 .

entities_list: @entity6565 :: ('MESH:D005368', 'Disease') :: ['filariasis']

entities_list: @entity20703 :: ('5530', 'Species') :: ['Metarhizium anisopliae']

entities_list: @entity2957 :: ('7176', 'Species') :: ['Culex quinquefasciatus']

entities_list: @entity313 :: ('7165', 'Species') :: ['Anopheles gambiae sensu stricto']

answer: @entity313 :: (7165,Species) :: ['Anopheles gambiae']


abstract: In many non-excitable and excitable cells, store-operated @entity460 entry (SOCE) represents an additional pathway for @entity460 entry upon @entity141 store depletion. In a previous study, we demonstrated SOCE activity in intact @entity19 cardiac pacemaker tissue, specifically from sinoatrial node (SAN) tissue. However, store content as a key determinant of SOCE activity is difficult to measure in intact SAN tissue. Therefore, to investigate the interaction between SOCE and store content and its role in cardiac pacemaking, it is necessary to investigate SOCE activity in single cardiac pacemaker cells. Furthermore, recent studies in other tissues have identified two new proteins involved in SOCE, stromal interacting molecule (STIM), which is an ER @entity141 sensor, and the surface membrane channel Orai, a prototypic gene encoding for SOCE. However, whether STIM and Orai are expressed in native pacemaker cells is still unknown. In this current study, we examined SOCE activity in single firing pacemaker cells isolated from @entity19 sinoatrial node tissue. We found a significant rise in @entity141 entry in response to @entity141 store depletion. SOCE blockers reduced the amplitude and frequency of spontaneous @entity141 transients and reduced @entity141 store content. We demonstrated for the first time that STIM and Orai are expressed in pacemaker cells. After store depletion, @entity17831 redistributed to the cell periphery and showed increased co-localization with surface membrane located @entity17832 , indicating a possible involvement of these proteins in SOCE activity in native cardiac pacemaker cells. These results suggest the novel concept that SOCE plays a functional role in regulating intracellular @entity141 of cardiac pacemaker cells.

title: Store-operated XXXX entry and the localization of @entity17831 and @entity17832 proteins in isolated @entity19 sinoatrial node cells.

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: OBJECTIVE: To evaluate the incidence of @entity3556 in @entity1 with @entity8052 according to gestational age at delivery. METHODS: This is a retrospective cohort study of @entity1 with prior cesarean delivery and persistent @entity5030 delivered at our institution between December 1997 and December 2011. Diagnosis of invasion was based on hysterectomy performed for an abnormally adherent placenta with histologic confirmation. Suspicion for invasion was based on the impression of the attending physician at the time of ultrasonography. Records were reviewed to identify indication for delivery and estimated @entity190 . Statistical analyses were performed using Student's t test,    test, and Mantel-Haenszel and Jonckheere-Terpstra tests for trend. RESULTS: Of 216 @entity1 with prior cesarean delivery and persistent previa, 65 (30%) required cesarean hysterectomy and had histologic confirmation of invasion. Urgent delivery for @entity548 was performed in 20% of these pregnancies (13/65). Delivery for @entity548 decreased significantly with advancing gestation (P=.001). In our series, 71% with accreta were delivered at 36 weeks of gestation or greater with delivery for @entity548 in five (11%), and estimated @entity190 was not increased in these pregnancies. Of 79 @entity1 with ultrasonographic suspicion for accreta, the incidence of @entity3556 prompting urgent delivery also decreased with advancing gestation (P<.001). CONCLUSION: Likelihood of @entity3556 necessitating delivery declined with advancing gestation in pregnancies with @entity8052 as did @entity190 . Most were delivered at 36 weeks of gestation or greater, nearly 90% in the absence of @entity548 complications. Thus, although @entity3152 is an important consideration when @entity8052 is suspected, our findings support individualizing delivery planning. LEVEL OF EVIDENCE: II.

title: Placenta Accreta and XXXX According to Gestational Age at Delivery.

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding']

entities_list: @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm delivery']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5030 :: ('MESH:D010923', 'Disease') :: ['placenta previa']

entities_list: @entity8052 :: ('MESH:D010921', 'Disease') :: ['placenta accreta']

answer: @entity3556 :: (MESH:D014592,Disease) :: ['Vaginal Bleeding']


abstract: UNASSIGNED: @entity30952 (ECoV) is a Betacoronavirus recently associated clinically and epidemiologically with @entity341 outbreaks of pyrogenic, @entity16 in @entity1641 in the United States, Japan, and Europe. We describe the pathologic, immunohistochemical, ultrastructural, and molecular findings in 2 @entity1641 and 1 @entity15382 that succumbed to natural infection with ECoV. One @entity1641 and the @entity15382 (case Nos. 1, 3) had severe @entity39 with marked villous attenuation, epithelial cell @entity39 at the tips of the villi, neutrophilic and fibrinous extravasation into the small intestinal lumen ( @entity8307 ), as well as crypt @entity39 , microthrombosis, and @entity548 . The other @entity1641 (case No. 2) had hyperammonemic @entity75 with @entity5718 throughout the cerebral cortex. ECoV was detected by quantitative polymerase chain reaction in small intestinal tissue, contents, and/or feces, and coronavirus antigen was detected by immunohistochemistry in the small intestine in all cases. Coronavirus-like particles characterized by spherical, moderately electron lucent, enveloped virions with distinct peplomer-like structures projecting from the surface were detected by negatively stained transmission electron microscopy in small intestine in case No. 1, and transmission electron microscopy of fixed small intestinal tissue from the same case revealed similar 85- to 100-nm intracytoplasmic particles located in vacuoles and free in the cytoplasm of unidentified (presumably epithelial) cells. Sequence comparison showed 97.9% to 99.0% sequence identity with the ECoV-NC99 and Tokachi09 strains. All together, these results indicate that ECoV is associated with necrotizing @entity1681 and hyperammonemic @entity75 in equids.

title: Necrotizing Enteritis and XXXX Associated With @entity30952 Infection in Equids.

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis', 'diffuse necrotizing enteritis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emerging']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['enteric, and/or neurologic disease']

entities_list: @entity8307 :: ('MESH:D004761', 'Disease') :: ['pseudomembrane formation']

entities_list: @entity30952 :: ('136187', 'Species') :: ['Equine coronavirus']

entities_list: @entity5718 :: ('MESH:C536595', 'Disease') :: ['Alzheimer type II astrocytosis']

entities_list: @entity1681 :: ('MESH:D004751', 'Disease') :: ['enteritis']

answer: @entity75 :: (MESH:D001927,Disease) :: ['Hyperammonemic Encephalopathy']


abstract: BACKGROUND: @entity1 with @entity162 have @entity149 , which are associated with poor functional outcomes. AIMS: This study evaluated the neurocognitive effects of @entity1770 in adolescents and young adults with @entity162 . METHODS: This was a 24-week, observational, prospective study performed in Taiwan. @entity1 in the study were clinically diagnosed as having @entity162 according to the Diagnostic and Statistical Manual of @entity146 , 4th edition (DSM-IV). In total, 28 @entity1 participated and were administered @entity1770 . Neurocognitive function was assessed as a change from baseline in the Continuous Performance Test (CPT) and the Wisconsin Card Sorting Test (WCST). RESULTS: The 28 @entity1 had a mean age of 18.5    3.3 years. During the 24-week @entity1770 treatment, these @entity1 had significant improvements in omission score (  (2) = 7.83, P = 0.050) and detectability scores (  (2) = 13.79, P = 0.003) in the CPT, and perseverative errors (  (2) = 17.42, P = 0.001) in the WCST. The WCST perseverative errors scores were significantly associated with general symptom scores in Brief Psychiatric Rating Scale (BPRS) (b = - 1.34, P = 0.024). No significant differences were found between the neurocognitive functions of @entity1 with @entity162 , @entity308 and mixed episodes from baseline to week 24. CONCLUSIONS: Adolescents and young adults with @entity162 experienced significant neurocognitive function improvements after treatment with @entity1770 . A randomized, controlled design is warranted to determine whether these improvements are associated with @entity1770 or the course of @entity162 .

title: Neurocognitive effects of @entity1770 in adolescents and young adults with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Participants']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['manic', 'bipolar disorder']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Mental Disorders']

entities_list: @entity149 :: ('MESH:D002493', 'Disease') :: ['neurocognitive impairments']

entities_list: @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar disorder']


abstract: AIMS: Preservation of the @entity11438 is advocated to reduce side effects of axillary dissection for @entity0 . We conducted a prospective randomized trail to compare functional results: @entity158 in preserved (group I) vs sacrificed (group II) @entity11438 ( @entity11438 ). METHODS: From July 1993 to April 1994, 128 @entity1 presenting with an invasive operable @entity0 were operated on by mastectomy n = 28 or lumpectomy n = 100 and axillary dissection. The @entity1 were eligible for randomization when the @entity11438 was preserved at the end of the axillary dissection. Group I (nerve preservation) included 66 @entity1 and group II (nerve section) 62 @entity1 . RESULTS: The two groups were well balanced for @entity2802 , type of surgery, number of nodes dissected and positive, post-operative adjuvant treatment. Examinations were conducted at 3, 6 and 12 months after surgery. @entity51 in the @entity11438 area was reported by one @entity1 in group I and four @entity1 in group II, at 3 months (P = 0.36, NS). No @entity1 , apart from one in group II, reported functional trouble at 18 months. Major shoulder motion, limitation and @entity158 developed in four @entity1 in group I and three in group II (NS). This was attributed to @entity308 and treated adequately. @entity51 was impossible in these @entity1 . CONCLUSIONS: Conservation of the @entity11438 , while anatomically preferable, is not functionally necessary during axillary dissection for @entity0 .

title: Preservation versus section of @entity11438 ( XXXX ) in axillary dissection for @entity0 --a prospective randomized trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity11438 :: ('MESH:D020968', 'Disease') :: ['intercostal-brachial nerve', 'IBN']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['Analysis of sensory deficit', 'Sensory deficit']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'sensory deficit and/or shoulder pain']

answer: @entity11438 :: (MESH:D020968,Disease) :: ['IBN']


abstract: The distribution of endothelin (ET) peptides in the @entity1707 was studied in a variety of tissues using selective radioimmunoassays combined with reverse-phase high performance liquid chromatography (HPLC). The levels of @entity3817 ( @entity3817 ) were overall relatively low. The highest levels of ET- @entity3817 were found in blood vessels, cerebral and coronary arteries containing 3190 +/- 910 and 1330 +/- 450 fmol/g, respectively. Veins generally contained higher levels of ET- @entity3817 per tissue weight than corresponding arteries. Peripheral sympathetic and sensory ganglia contained a higher concentration of ET- @entity3817 than the studied central nervous system (CNS) areas. In the CNS the highest concentration of ET- @entity3817 was found in a non-neuronal structure, the choroid plexus. The levels of ET- @entity3817 were also relatively high in the respiratory tract (100-400 fmol/g). In the heart, the endocardium contained the highest levels (190 +/- 44 fmol/g). In the kidney, the concentration of ET- @entity3817 was 3-fold higher in the medulla than in the cortex. In the gastrointestinal tract all levels were below 100 fmol/g, except for the colon which contained 120 +/- 50 fmol/g. The characterization of ET- @entity3817 in extracts of some of these tissues revealed that @entity18512 dominated in the lung, spleen and hypothalamus while @entity54283 and @entity18512 were present in approximately equal amounts in renal medulla and thoracic spinal cord. The HPLC analysis provided no clear-cut evidence for significant presence of vasoactive intestinal contractor, ET-2 or big @entity18512 (1-39) in the lung, spleen, kidney, spinal cord or hypothalamus. It is concluded that mature @entity20074 are the predominant ET peptides in peripheral tissues and CNS.

title: Presence of @entity18512 and XXXX in peripheral tissues and central nervous system of the @entity1707 .

entities_list: @entity3817 :: ('MESH:C537505', 'Disease') :: ['LI', 'ET-like immunoreactivity']

answer: @entity54283 :: (100049663(Tax:9823),Gene) :: ['endothelin-3']


abstract: AIM: This article is a report of a study conducted to explore the perceptions of adults with type 2 @entity6 towards the service redesign. BACKGROUND: @entity6 is reaching epidemic proportions and the management of this @entity102 is changing in response to this challenge. In the United Kingdom, there is ongoing restructuring of healthcare services for @entity1 with @entity102 to ensure that their general health and clinical needs are met predominantly in primary care. METHOD: An explorative qualitative approach was used. Eight focus groups were conducted with 35 @entity1 with type 2 @entity6 in one urban location between 2003 and 2004. Five focus groups were conducted with @entity1 who had recently experienced the restructured service and three groups with @entity1 who had up to 2 years' experience of the new service. Concurrent data collection and thematic analysis were conducted by three researchers and credibility and verification sought by feedback to @entity1 . FINDINGS: Five main themes were identified: impact of living with @entity6 ; understanding @entity6 ; drivers for organizational change; care in context and individual concerns. @entity1 identified issues for ongoing development of the service. CONCLUSION: @entity1 with type 2 @entity6 appreciate their care management within the primary care setting where there has been investment in staff to deliver this care. Healthcare resources are required to support the development of staff and the necessary infrastructure to undertake management in primary care. Policy makers need to address the balance of resources between primary and secondary care.

title: Perceptions of a service redesign by adults living with type 2 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'people', 'People']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic illnesses', 'chronic illness']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: The objectives of this study were to determine the effect of administration of exogenous @entity1176 5days after artificial insemination (AI) on ovarian structures, serum @entity1420 concentration, and conception rates in lactating dairy @entity291 . In experiment 1, 23 Holstein @entity291 were synchronized using the Ovsynch protocol. Five days after AI (day 0) @entity291 were assigned randomly to receive either saline (saline; n=11) or 100microg @entity1176 ( @entity1176 ; n=12). To examine ovarian structures, ultrasonography was performed on day 1 and every other day beginning on day 5 until day 13. On days 5 and 13 blood samples were obtained to measure serum @entity1420 concentrations. All @entity291 in the @entity1176 -treated group developed an accessory corpus luteum (CL), whereas @entity291 in the saline group did not. Mean serum @entity1420 concentrations did not differ between @entity1176 and saline groups on day 5 (1.64+/-0.46ng/ml versus 2.04+/-0.48ng/ml). On day 13 serum @entity1420 concentrations were greater (P<0.05) in the @entity1176 group compared with saline (5.22+/-0.46ng/ml versus 3.36+/-0.48ng/ml). In experiment 2, 542 lactating @entity291 , at two different commercial dairies, were used to test the effect of administering @entity1176 5 days after AI on conception rates. @entity291 were synchronized and detected for estrus according to tail chalk removal. @entity291 detected in estrus received AI within 1h after detection of estrus. Five days after AI, @entity291 were assigned randomly to receive either @entity1176 (n=266) or saline (n=276). Pregnancy status was determined by palpation per rectum of uterine contents approximately 40 days after AI. There was no effect of farm on conception rate. There was no effect of treatment as conception rates did not differ between @entity1176 and saline groups (26.7% @entity1176 versus 24.3% saline). Regardless of treatment, days in milk, parity, milk yield, and number of services had no effect on the odds ratio of pregnancy. In summary, the results of this study indicated that @entity1176 administered 5 days after AI increased serum @entity1420 by developing an accessory CL but did not improve conception rates in dairy @entity291 .

title: Conception rates and serum XXXX concentration in dairy @entity291 administered gonadotropin releasing hormone 5 days after artificial insemination.

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

answer: @entity1420 :: (MESH:D011374,Chemical) :: ['progesterone']


abstract: @entity2915 of coagulation factor @entity797 ( @entity2801 ) @entity49 . @entity2801 enhances activity of factor IX and their combination activates factor X, which is of primary importance in prothrombin transformation into thrombin, on the phospholipid membrane. The activity of @entity2801 was studied in 28 @entity1 (26 @entity1 , 2 @entity1 , mean age 49.6 +/- 7.8 years) with @entity12287 ( @entity12287 ). @entity12287 manifests clinically similarly to @entity1701 ( @entity1701 ). The leading of them are ischemic disorders of cerebral circulation (IDCC) and advanced livedo present in all the examinees. @entity2915 of @entity2801 was registered in 21 (75%) of 28 @entity1 . Most of @entity715 -related symptoms occurred more frequently in @entity1 with high than normal activity of @entity2801 : @entity385 (91% vs 57%, p > 0.05), repeated @entity64 (71% vs 0%, p = 0.0014), transient IDCC (76% vs 57%, p > 0.05), @entity1294 (43% vs 0%, p > 0.05), @entity741 (43% vs 0%, p > 0.05), thickening of heart valves according to echocardiography (91% vs 57%, p > 0.05), peripheral @entity1150 (24% vs 0%, p > 0.05). In high @entity2801 activity cardiolipin antibodies occurred more rarely (24% vs 43%, p > 0.05) but lupus anticoagulant was seen more often (47% vs 14%, p > 0.05). High @entity2801 activity was in 8 of 12 aPL-negative @entity1 . It is demonstrated that elevated @entity2801 activity is an essential mechanism of @entity715 development in @entity12287 . The cause of this enhanced activity is suggested to be special aPL in interaction with which @entity2801 becomes insensitive to inactivation with protein C. The activity of protein C was normal in all the cases.

title: [Clotting factor XXXX in @entity12287 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes']

entities_list: @entity1294 :: ('MESH:D015140', 'Disease') :: ['vascular dementia']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['marks hypercoagulation']

entities_list: @entity1701 :: ('MESH:D016736', 'Disease') :: ['PAS', 'primary antiphospholipid syndrome']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['venous thromboses']

entities_list: @entity12287 :: ('MESH:D018860', 'Disease') :: ['SS', "Sneddon's syndrome"]

entities_list: @entity2915 :: ('MESH:D006948', 'Disease') :: ['Hyperactivity']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['ischemic heart disease']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic strokes']

answer: @entity797 :: (1351,Gene) :: ['VIII']


abstract: UNASSIGNED: @entity6948 ( @entity9170 ) is a selective a2 adrenergic agonist that is commonly used for sedation in the intensive care unit (ICU). The role of @entity9170 for adjunctive treatment of @entity428 is poorly defined. The primary objective of this study was to determine the effect of @entity9170 on the need for rescue therapy (ie, hyperosmolar boluses, extraventricular drain [EVD] drainages) for @entity428 . Secondary objectives included the number of @entity428 ( @entity428 ) excursions, bradycardic, @entity551 , and compromised cerebral perfusion pressure episodes. This retrospective cohort study evaluated @entity1 admitted to the neurosurgical ICU from August 1, 2009, to July 29, 2015, and who received @entity9170 for @entity428 . The objectives were compared between the 2 time periods-before (pre- @entity9170 ) and during therapy ( @entity9170 ). Twenty-three @entity1 with 26 episodes of @entity428 met the inclusion criteria. The number of hyperosmolar boluses was decreased after @entity9170 therapy was initiated. @entity2656 boluses required were statistically reduced (1 vs 0.5, P = .03); however, @entity4372 was not statistically significant (1.3 vs 0.9, P = .2). The mean number of EVD drainages per 24 hours was not significantly different between the time periods (15.7 vs 14.0, P = .35). The rate of @entity428 excursions did not differ between the 2 groups (24.3 vs 22.5, P = .62). When compared to pre- @entity9170 data, there was no difference in the median number of @entity551 (0 vs 0), bradycardic (0 vs 0), or compromised cerebral perfusion pressure episodes (0.5 vs 1.0). @entity6948 may avoid increases in the need for rescue therapy when used as an adjunctive treatment of @entity428 without compromising hemodynamics.

title: XXXX for Refractory Intracranial Hypertension.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['Mannitol']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['refractory intracranial hypertension', 'ICP', 'intracranial pressure']

entities_list: @entity4372 :: ('MESH:D009122', 'Disease') :: ['reduction in hypertonic boluses']

entities_list: @entity6948 :: ('MESH:D020927', 'Chemical') :: ['Dexmedetomidine']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive']

answer: @entity6948 :: (MESH:D020927,Chemical) :: ['Dexmedetomidine']


abstract: PURPOSE: To report the characteristics and laboratory findings of 182 @entity1 with @entity1036 diagnosed at Farabi Eye Hospital in Tehran, Iran. MATERIALS AND METHODS: In this retrospective study, data were collected on demographics, risk factors, location, size and depth of the @entity1066 , height of the hypopyon, uncorrected visual acuity, results of smear and culture tests, and antibiotic sensitivity of cultured bacteria. RESULTS: There were 110 (60.4%) males and 72 (39.6%) females with an average age of 56.0    2.3 years. Ocular @entity130 (17.6%) and positive history of corneal surgery (14.3%) were major risk factors. The mean age of contact lens users was 22.5    7.7 years. Sixty @entity1 (33%) used topical antibiotics, 21 (11.5%) @entity1 utilized topical @entity479 , and 26 (14.3%) cases used both topical antibiotic and @entity479 at presentation. Culture results were, 81 (44.5%) cases were Gram-positive, 63 (34.6%) were Gram-negative, 10 (5.5%) were mixed bacteria and in 28 (15.4%) cases had detected growth. The isolated bacterial species from the corneal @entity1066 were less resistant to @entity5505 (6%) and @entity4509 (6%). The majority of @entity1 were treated with medical therapy; however, 81 cases (44.5%) received at least one surgical procedure. CONCLUSION: Among the @entity1 with @entity3283 , @entity130 was the most common risk factor. Over-the-counter antibiotic and @entity479 were commonly used in the majority of @entity1 . The most common bacteria isolated were Gram-positives, and they were less resistant to @entity5505 and @entity4509 . Penetrating keratoplasty was the most common surgical procedure in @entity1 who required surgery.

title: XXXX in a tertiary eye centre in iran: a retrospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1036 :: ('MESH:D007634', 'Disease') :: ['bacterial keratitis']

entities_list: @entity4509 :: ('MESH:D000583', 'Chemical') :: ['amikacin']

entities_list: @entity3283 :: ('MESH:D003320', 'Disease') :: ['bacterial corneal ulcers']

entities_list: @entity5505 :: ('MESH:D002442', 'Chemical') :: ['ceftazidime']

answer: @entity1036 :: (MESH:D007634,Disease) :: ['Bacterial keratitis']


abstract: BACKGROUND: The pathophysiology of @entity1468 ( @entity1468 ) is complex, and @entity842 (NO) may be a factor. The neonatal outcome in pregnancies complicated by @entity1468 is controversial, and the @entity1468 /NO/neonatal diseases relationship has not been well established. AIMS: To measure @entity1507 and @entity3542 levels in the placenta, umbilical cord blood, blood and urine of preterm neonates born to pre-eclamptic and normotensive @entity1 and to investigate the relationship between placental, fetal and neonatal NO metabolites and neonatal outcome. METHODS: A prospective study was undertaken of 30 preterm @entity1 <34 weeks of gestation, born to pre-eclamptic mothers and matched by gestational age with 30 @entity1 born to normotensive mothers. Samples from the placental tissue, @entity7239 and the newborns' blood on day 4 and urine on days 1 and 4 were assayed for NO metabolites ( @entity1507 and @entity3542 ). Clinical variables and NO metabolites were compared between the groups. Generalised linear models were fitted to associate NO metabolites levels with adverse neonatal outcomes. RESULTS: There were no differences in NO metabolites and neonatal outcomes between the two groups. Increased levels of NO metabolites were found in the placenta and cord blood of small-for-gestational-age @entity1 , and in the cord blood of newborns with @entity1964 and those who died. CONCLUSION: NO metabolite levels in the placenta and fetal and neonatal circulation were not associated with @entity1468 ; however, cord blood levels of NO metabolites differed according to fetal growth and neonatal outcome.

title: There is no difference in @entity842 metabolites and neonatal outcome between premature @entity1 born to pre-eclamptic and those born to normotensive XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'infants']

entities_list: @entity7239 :: ('MESH:D020758', 'Disease') :: ['venous cord blood']

entities_list: @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['pre-eclampsia', 'PE']

entities_list: @entity1964 :: ('MESH:D004760', 'Disease') :: ['necrotising enterocolitis']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: INTRODUCTION: In @entity233 , pharmacovigilance began in 1985. A fully structured adverse drug reaction (ADR)-reporting system was established with the publication of the first pharmacovigilance regulation in 2005. Subsequent regulation published in 2014 brought further improvements to the system. OBJECTIVE: In this study, we aimed to analyse the ADR-reporting pattern in the context of the first pharmacovigilance legislation in @entity233 . METHODS: We analysed ADR reports submitted to the Turkish Pharmacovigilance Center (TUFAM) from 2005 to 2014 with respect to reporting rate (RR), @entity1 characteristics, type of the ADRs, suspected drugs, source of the report and the profession of the reporter. RESULTS: The annual RR increased gradually over the study period. RRs for females were greater than those for males. RRs were highly correlated with age. Most commonly reported ADRs were skin and @entity3145 . Most commonly suspected drugs were antineoplastic and immunomodulating agents. There was no remarkable change in reporting pattern of ADRs, @entity1 characteristics or classes of suspected drugs over the years. The most common source of reports was spontaneous reporting. Contribution of the reports from studies increased gradually. Most of the reports were reported by physicians. RRs by pharmacists increased substantially over the years. CONCLUSION: This study showed that the annual RR increased gradually over the 9-year study period. This increase was neither due to an increased reporting of a specific group of ADRs or drugs, nor to an increased reporting in a specific group of @entity1 . There was a general increase in RR in parallel to pharmacovigilance activities.

title: Adverse Drug Reaction Reporting Pattern in XXXX : Analysis of the National Database in the Context of the First Pharmacovigilance Legislation.

entities_list: @entity3145 :: ('MESH:D017695', 'Disease') :: ['subcutaneous tissue disorders']

answer: @entity233 :: (9103,Species) :: ['Turkey']


abstract: 1. A variety of @entity2918 were examined for their ability to alter the periarterial nerve stimulation-induced release of @entity1063 (NA) and neuropeptide Y immunoreactive compounds ( @entity10969 -ir) from the perfused mesenteric arterial bed of the @entity35 . 2. @entity129 (16 Hz) increased the overflow of NA, @entity10969 -ir and perfusion pressure. 3. The prostacyclin (PGI2) analogues, carbaPGI2 and cicaprost both produced a concentration-dependent attenuation of the nerve stimulation-induced increase in NA, @entity10969 -ir overflow and perfusion pressure. 4. The @entity3009 (PG) analogue @entity1421 attenuated the evoked increase in @entity10969 -ir overflow as well as a modest decrease in NA. 5. @entity5015 , @entity6002 and iloprost attenuated the nerve stimulation-induced increase in NA overflow but not @entity10969 -ir. 6. Neither PGF2alpha nor the @entity2404 analogue @entity2872 altered the evoked increase in NA or @entity10969 -ir overflow. 7. The results support the view that sympathetic co-transmitter release can be differentially modulated by paracrine/autocrine mediators at sympathetic neuroeffector junctions.

title: Prostanoid-induced modulation of neuropeptide Y and @entity1063 release from the XXXX mesenteric bed.

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['Periarterial nerve stimulation']

entities_list: @entity2404 :: ('MESH:D013928', 'Chemical') :: ['thromboxane A2']

entities_list: @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostanoids']

entities_list: @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin']

entities_list: @entity6002 :: ('MESH:C016767', 'Chemical') :: ['sulprostone']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND/OBJECTIVES: The aim of the study was to evaluate the volume of intraocular foreign bodies (IOFB) using computed tomography (CT) volumetry as a prognostic factor for clinical outcome in open @entity4858 . @entity1 AND METHODS: This study compared the volume of 11 IOFBs more than 5  mm(3) in size based on CT volumetry with the real size determined by in vitro measurement. A retrospective evaluation of clinical data, visual acuity, complications and relation of size of IOFBs with clinical outcome in 33 @entity1 (mean age 41.0        13.5 years) with open @entity4858 treated at our department between January 2005 and December 2010 was carried out. RESULTS: No significant differences were found between pairwise in vitro measurement and CT volumetric size (p   =   0.07). All @entity1 were surgically treated by pars plana vitrectomy. The mean follow-up time was 7.6     6.2 months and the mean preoperative best corrected visual acuity (BCVA) was 0.063        0.16 (logMAR 1.2        0.79). Postoperatively, a mean BCVA of 0.25        0.2 (logMAR 0.6        0.69) could be achieved. Clinical outcomes were significantly better in injuries with small IOFBs measuring <   15  mm(3) (p   =   0.0098). CONCLUSIONS: The use of CT volumetry is an accurate method for measurement of IOFBs. Exact data about the size and measurement of volume are also an important factor for the prognosis of clinical outcome in open @entity4858 with IOFBs and CT volumetry can also provide important information about the localization of IOFBs.

title: [Accuracy and relevance of CT volumetry in open XXXX with intraocular foreign bodies.]

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients']

entities_list: @entity4858 :: ('MESH:D005131', 'Disease') :: ['ocular injuries']

answer: @entity4858 :: (MESH:D005131,Disease) :: ['ocular injuries']


abstract: @entity1 with pyloric channel and @entity2275 are often considered to have an @entity1066 diathesis similar to @entity1 with duodenal @entity1066 , while @entity1 with more @entity2275 (ie, fundus, body, antrum) are excluded. To evaluate possible differences in basal acid outputs with regard to gastric @entity1066 location, basal acid outputs were determined by nasogastric suction in 80 @entity1 with endoscopically documented benign active @entity2275 . The results were compared to 65 normal subjects and 155 @entity1 with endoscopically documented duodenal @entity1066 . There were no significant differences in basal acid outputs among the 80 @entity1 with @entity2275 with regard to location (ie, fundus-body, antrum, prepyloric, channel), and no significant differences compared to the 65 normal subjects. However, basal acid output for the 155 @entity1 with duodenal @entity1066 was significantly different from the 80 @entity1 with @entity2275 (P < 0.05) and the 65 normal subjects (P < 0.05). Basal acid outputs tended to be higher and there was more gastric acid hypersecretion when @entity2275 were located near the pylorus. However, irrespective of gastric @entity1066 location, basal acid outputs were higher in @entity1 with duodenal @entity1066 . Seventy-one of the 80 @entity1 with @entity2275 were treated for eight weeks with standard doses of antisecretory medications, and endoscopic healing or nonhealing was documented. In 60 @entity1 their @entity2275 completely healed, while 11 @entity1 had nonhealed @entity2275 . There were no significant differences between the two groups with regard to gender, mean age, or basal acid output.(ABSTRACT TRUNCATED AT 250 WORDS)

title: XXXX differ from duodenal @entity1066 . Evaluation of basal acid output.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2275 :: ('MESH:D013276', 'Disease') :: ['gastric ulcers', 'prepyloric gastric ulcers', 'proximal gastric ulcers']

answer: @entity2275 :: (MESH:D013276,Disease) :: ['Gastric ulcers']


abstract: BACKGROUND: Broncho-alveolar lavage (BAL) is an invasive bedside procedure to define type and concentration of pathologic organisms causing ventilator associated @entity55 (VAP). We evaluated if the absence of pathogens on final results represented a lavage aspect of the BAL as a therapeutic procedure to eliminate organisms. METHODS: BAL results collected from 2008 to 2009 were stratified as positive (POS) >=  100,000 cfu), indeterminate (INT)  <= 100,000 cfu pathologic organisms, or negative defined as @entity325 ( @entity325 ) or sterile (STR). The INT, @entity325 , and STR results were assessed by incidence of a subsequent POS sample. RESULTS: Nine-hundred forty-nine BALs performed on 490 SICU @entity1 were interpreted as POS in 227 @entity1 (46%). 237 non- POS @entity1 needed a subsequent BAL. Any pathogen on the first BAL (INT group) indicates a high likelihood for subsequent BAL which will be POS. Monthly cumulative sum analysis (CUSUM) of yield was unable to identify any specific period in which BAL performance varied from trend. CONCLUSION: @entity325 and STR represent adequate sampling of secretions that are clinically benign. Any pathogen, regardless of concentration, should be considered a biomarker for future @entity55 . CUSUM analysis suggest better training in timing and indication may decrease unnecessary procedures yielding negative results.

title: Risk stratification for the development of a subsequent XXXX after a nondiagnostic bronchoalveolar lavage.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity325 :: ('MESH:D060085', 'Disease') :: ['MF', 'mixed flora']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

answer: @entity55 :: (MESH:D011014,Disease) :: ['pneumonia']


abstract: The Ig idiotype of @entity1892 can be used as a @entity5 -specific target. Prior trials with monoclonal anti-idiotype antibodies alone and combined with alpha-interferon have shown significant antitumor activity. In some @entity1 , idiotype-negative @entity5 emerged after treatment. In this trial, @entity1 with relapsed @entity1893 were treated with two identical courses of monoclonal anti-idiotype anti-body therapy. Concurrent with the second course, at a time when idiotype-negative cells were suspected to be proliferating, a pulse dose of @entity5805 was administered. Tumor biopsies obtained before the first and second courses of treatment and at relapse were analyzed for idiotype expression and proliferation. Thirteen @entity1 received 24 courses of antibody with minimal @entity137 . Eleven had @entity5 regression, with 1 complete remission, 8 partial remissions, and 2 minor remissions, with freedom from progression lasting a median of 7 months in responding @entity1 . Idiotype-negative @entity5 cells appeared in some relapse specimens despite the use of @entity5805 . In retrospect, this was not surprising because there was no increase in the proliferative rate of these @entity5 at the time the drug was used. Anti-idiotype antibodies continue to demonstrate antitumor activity against @entity1892 with minimal @entity137 . The mechanism of the effect is presumed to involve both direct antiproliferative effects of the antibody on the @entity5 cells as well as indirect, more long-lasting effects on the host. The addition of a mild chemotherapeutic agent in the dose and schedule used here to the second cycle of antibody therapy did not interfere with the antitumor effect, nor did it decrease the emergence of idiotype-negative cells.

title: Monoclonal anti-idiotype antibody therapy of XXXX : the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity5805 :: ('MESH:D002699', 'Chemical') :: ['chlorambucil']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"]

answer: @entity1892 :: (MESH:D016393,Disease) :: ['B-cell lymphoma']


abstract: BACKGROUND: @entity9608 resection (LIR) for @entity66 is increasingly supported as a feasible and safe operation in small series of @entity1 . To determine whether LIR is an acceptable alternative to the open operation, it is necessary to compare LIR to historical controls. The purpose of this study was to identify the skills and technology needed for LIR and establish outcome standards. METHODS: A database of @entity1 with @entity9608 who underwent an open procedure at the Mayo Clinic was reviewed for demographics, imaging, operative/pathology reports, and outcomes. Outcomes were compared to a world-wide meta-analysis of @entity1 who had undergone LIR reported in the English literature between 1996 and 2009. RESULTS: Two hundred fifteen @entity1 underwent a primary open operation for @entity9608 . @entity5 were found in 97%. Meta-analysis identified 232 @entity1 who underwent LIR. The open and LIR groups underwent comparable operations that included enucleations (64 vs. 68%) and distal pancreatectomies (28 vs. 35%) (p = 0.06). The mean estimated @entity190 , operating time, and length of stay were comparable between the open and LIR groups (p = NS). @entity3472 occurred more often in the LIR group (24 vs. 11%, p < 0.05). A curative operation was performed in 98% of control @entity1 and in 99% of the LIR group (p = NS). CONCLUSIONS: @entity9608 are rare and a focused resection guided by imaging may be performed. LIR is associated with an increased incidence of @entity3472 . Success of LIR will depend on accurate multimodality preoperative imaging, skilled use of lap-US to replace palpation for localization, and safe methods to dissect the @entity5 adjacent to the pancreatic duct.

title: Setting the bar for laparoscopic resection of XXXX .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['sporadic disease']

entities_list: @entity9608 :: ('MESH:D007340', 'Disease') :: ['Laparoscopic insulinoma', 'benign sporadic insulinoma', 'Multiple insulinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solitary tumors']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity3472 :: ('MESH:D010185', 'Disease') :: ['Pancreatic fistula', 'pancreatic fistula']

answer: @entity9608 :: (MESH:D007340,Disease) :: ['sporadic insulinoma']


abstract: Past research examined measures of @entity158 among seniors who were experiencing movement-related exacerbations of @entity4512 and obtained clear support for the utility of the behavioural coding of @entity158 (e.g., bracing, guarding). Support for the utility of the Facial Action Coding System (FACS), which involves the objective coding of facial reactions, was not as strong. The findings concerning FACS could have been an artifact of the methodology that was used. Specifically, the duration of the facial reactions was not taken into account and the @entity1 suffered from a variety of @entity158 conditions. Thus, the physical activities involved in the study could have been @entity158 for some @entity1 but not for others. The present study corrected these methodological concerns by accounting for the duration of facial reactions and ensuring that all @entity1 suffered from the same @entity158 . @entity1 were 82 post-surgical (knee replacement) inpatients. Cognitive status was assessed using the Modified Mini Mental Status Examination. Under physiotherapist's supervision, the @entity1 performed structured activities (i.e., reclining, standing, knee bends). Facial reactions were coded using FACS. Facial reactions varied as a function of the degree to which the various activities were strenuous. The results support the utility of FACS in the assessment of @entity4512 among seniors undergoing rehabilitation following knee surgery.

title: Using facial expressions to assess XXXX in older @entity1 .

entities_list: @entity4512 :: ('MESH:D059352', 'Disease') :: ['musculoskeletal pain']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['painful condition', 'pain', 'pain-related body movements', 'painful']

answer: @entity4512 :: (MESH:D059352,Disease) :: ['musculoskeletal pain']


abstract: PURPOSE: To report the results of same-day triple therapy with reduced fluence photodynamic therapy, intravitreal @entity619 , and bevacizumab in @entity1 with neovascular age-related @entity1020 . METHODS: Retrospective case series. Records of @entity1 who received same-day triple therapy with reduced fluence photodynamic therapy (25 J/cm), intravitreal @entity619 (200 microg), and intravitreal bevacizumab (1.25 mg) were reviewed. All @entity1 had neovascular subfoveal age-related @entity1020 with at least 1 year of follow-up. Snellen visual acuity (VA), central macular thickness on optical coherence tomography, intraocular pressure, and @entity3225 occurrence were recorded. RESULTS: The 31 @entity1 were observed for a mean of 13.7 months. In all @entity1 , mean baseline VA was 20/80 and vision at final follow-up was 20/60 (P = 0.69). In @entity1 who received previous treatment for exudative age-related @entity1020 (n = 18), mean baseline VA was 20/100 and vision at final follow-up (mean, 13.7 months) was 20/100 (P = 0.31). In treatment-na  ve @entity1 (n = 13), mean baseline VA was 20/60 and vision at final follow-up (mean, 13.5 months) was 20/40 (P = 0.31). In all @entity1 , mean central macular thickness was 293 mum at baseline and 245 mum at final follow-up (P = 0.053). In previously treated @entity1 (n = 18), mean central macular thickness was 325 mum at baseline and 265 mum at final follow-up (P = 0.10). In treatment-na  ve @entity1 , mean central macular thickness was 249 mum at baseline (n = 13) and 218 mum at final follow-up (P = 0.34). Previously treated @entity1 required more antivascular endothelial growth factor injections (mean = 3.6) than treatment-na  ve @entity1 (mean = 0.8), but the mean number of repeat triple therapy treatments was 0.3 in both groups. Changes in intraocular pressure and @entity3225 were not observed during follow-up. CONCLUSION: Same-day triple therapy maintained VA and decreased macular thickness in @entity1 with and without previous antivascular endothelial growth factor therapy. Triple therapy may reduce the number of antivascular endothelial growth factor injections in some @entity1 and stabilize vision in some @entity1 not responding to antivascular endothelial growth factor therapy.

title: Same-day triple therapy with photodynamic therapy, intravitreal XXXX , and bevacizumab in wet age-related @entity1020 .

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity3225 :: ('MESH:D009877', 'Disease') :: ['endophthalmitis']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: @entity364 is a rare but sight-threatening @entity281 that may be caused by several fungal pathogens. A delay in diagnosis and inadequate treatment may even lead to loss of the affected eye. @entity364 is often misdiagnosed as @entity1036 because isolation and identification of the fungal pathogen is difficult and requires experience, and fungal growth in culture requires time. In this report, a 14-year-old @entity1 with recalcitrant @entity10437 keratitis, unresponsive to initial therapy, is presented. CLSI M38-A2 in vitro antifungal susceptibility tests demonstrated that only @entity2379 (0.5  g/ml) had potent activity against @entity10437 ; however, @entity2380 (>64  g/ml), @entity2059 (>16  g/ml), @entity5074 (8  g/ml), and @entity7143 (>16  g/ml) had high minimum inhibitory concentrations. In addition, @entity11794 (>16  g/ml) and @entity25928 (>16  g/ml) exhibited high minimum effective concentrations. Repeated intrastromal @entity5074 injections, topical @entity5074 , and @entity11794 combined with systemic antifungal agents improved of the @entity2687 with a significant increase in visual acuity. Intrastromal @entity5074 injection may be used as an adjunctive treatment method for recalcitrant @entity364 with no prominent complications. The intrastromal route could be an effective route of administration of antifungal agents, especially for @entity10437 keratitis, as in this case. A combination of various antifungal agents administered by different routes prevented @entity735 .

title: Successful medical management of recalcitrant XXXX keratitis: molecular identification and susceptibility patterns.

entities_list: @entity25928 :: ('MESH:C102786', 'Chemical') :: ['anidulafungin']

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

entities_list: @entity1036 :: ('MESH:D007634', 'Disease') :: ['bacterial keratitis']

entities_list: @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole']

entities_list: @entity10437 :: ('169388', 'Species') :: ['Fusarium solani', 'F. solani']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection of the cornea']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['Fungal keratitis', 'fungal keratitis']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['loss of the eye']

entities_list: @entity2687 :: ('MESH:D003316', 'Disease') :: ['corneal lesion']

entities_list: @entity5074 :: ('MESH:C102790', 'Chemical') :: ['voriconazole']

entities_list: @entity7143 :: ('MESH:C101425', 'Chemical') :: ['posaconazole']

entities_list: @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']

entities_list: @entity11794 :: ('MESH:C105417', 'Chemical') :: ['caspofungin']

answer: @entity10437 :: (169388,Species) :: ['Fusarium solani']


abstract: OBJECTIVE: This study aimed to evaluate differences in transcranial electrical motor evoked potential (tcMEP) amplitudes between @entity10233 / @entity1937 and @entity1875 / @entity1937 anesthesia treatment plans in @entity1 without @entity51 ( @entity51 ) undergoing carotid endarterectomy (CEA). METHODS: This prospective trial included 21 @entity1 who were randomly assigned to an effect group (Group( @entity10233 ); n=14) or a control group (Group(STANDARD- @entity1875 ); n=7). tcMEP amplitudes were measured 35min post-induction (T1) either with @entity10233 or @entity1875 . Treatment was then changed to @entity1875 in Group( @entity10233 ). After an additional 35min, the tcMEP amplitudes were reevaluated (T2). Differences in amplitudes (DW) between T1 and T2 were calculated for each @entity1 , and the means of these differences were compared between groups. RESULTS: tcMEPs were recorded in all 21 @entity1 . At T1, the mean amplitude was 840.1 (SD 50.3) V and 358.9 (SD 74) V for Group(STANDARD- @entity1875 ) and Group( @entity10233 ), respectively. The absolute mean difference (T1-T2) between groups was -496.75 V (p=0.0006). CONCLUSION: @entity10233 reduces the tcMEP amplitude significantly more than @entity1875 in @entity1 without @entity51 undergoing CEA. SIGNIFICANCE: TcMEPs were recorded in all @entity1 regardless of the anesthesia regimen. In @entity1 with initially small amplitudes, @entity10233 may limit tcMEP recording because it produces a remarkable amplitude reduction, even in @entity1 without @entity51 .

title: Transcranial motor evoked potentials during anesthesia with XXXX versus @entity1875 - A prospective randomized trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['preexisting motor deficits', 'PMDs']

entities_list: @entity10233 :: ('MESH:C053562', 'Chemical') :: ['desflurane', 'DESFLURANE', 'Desflurane']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'PROPOFOL']

entities_list: @entity1937 :: ('MESH:C071741', 'Chemical') :: ['remifentanil']

answer: @entity10233 :: (MESH:C053562,Chemical) :: ['desflurane']


abstract: BACKGROUND/AIMS: It has been hypothesized that the intrauterine environment is an independent factor in @entity28 development. If so, the maternal effect is likely to be a stronger influencing factor ('fetal @entity4084 hypothesis'). We aimed to systematically evaluate the associations of offspring body mass index (BMI, or adiposity) with pre-pregnancy BMI (or adiposity) of the mother and the father. METHODS: The Medline, Embase and Cochrane Library databases were searched in March 2012. RESULTS: Seven cohort studies were eligible for the analysis. Among these, 2 groups of trials presented different data from the same parent-offspring cohorts (the Avon Longitudinal Study of Parents and @entity1 , ALSPAC, and the Mater-University Study of Pregnancy, MUSP). In total, 3 large birth cohorts and 1 additional small study were identified. Three studies provided a direct comparison of parent-offspring associations, with a statistically stronger maternal influence found only in the MUSP cohort. Equivocal results were obtained from all studies describing the ALSPAC cohort. The parental effect (indirectly estimated based on the presented odds ratio) was similar in the Finnish cohort. In 1 additional small study, maternal BMI was found to be a strong predictor of @entity28 . CONCLUSIONS: There is only limited evidence to support the 'fetal @entity4084 hypothesis'.

title: Maternal and paternal body mass index and offspring XXXX : a systematic review.

entities_list: @entity1 :: ('9606', 'Species') :: ['Children']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['childhood obesity', 'obesity']

entities_list: @entity4084 :: ('MESH:D044343', 'Disease') :: ['overnutrition']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: OBJECTIVE: The aim was to clinically and microbiologically describe the periodontal conditions in a remote adult Asian population with poor oral hygiene. METHODS: The subjects were 30-60-year-old adults of Karen Hill tribes with no access to dental care. Eighty-six subjects were selected randomly. Clinical registrations included number of remaining teeth, plaque index (PlI), @entity548 on probing (BoP), clinical @entity6730 (CAL), and @entity5951 ( @entity5951 ). @entity527 samples were collected and analyzed with the checkerboard method. RESULTS: Subjects of the study group had mean number of remaining teeth of 26.5 despite the abundant plaque and a high @entity548 score. Severe @entity2521 (CAL  >=   7  mm) was recorded in 12.9% of the youngest age group (30-39 years) while it was significantly higher (52%) in the middle group (40-49 years) and (60%) in the eldest age group (50-60  years). Pathological pocketing ( @entity5951  >=   7  mm) was significantly lower in all age groups. Age, betel chewing, and a microbiological cluster including at least one of Prevotella tannerae, @entity59967 and Porphyromonas endodontalis significantly correlated with the severity of @entity2520 . CONCLUSION: Age, betel chewing, and a new bacterial complex other than the "red complex" correlated to periodontal breakdown in this remote adult Asian population.

title: XXXX in a remote Asian population: association between clinical and microbiological parameters.

entities_list: @entity6730 :: ('MESH:D017622', 'Disease') :: ['attachment loss']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['Subgingival plaque']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

entities_list: @entity59967 :: ('143361', 'Species') :: ['Filifactor alocis']

entities_list: @entity5951 :: ('MESH:D005888', 'Disease') :: ['PPD', 'probing pocket depth']

answer: @entity2520 :: (MESH:D010510,Disease) :: ['Periodontal disease']


abstract: @entity120 ( @entity120 ) is a progressive @entity455 of pulmonary arteries that impedes ejection of blood by the right ventricle. As a result there is an increase in pulmonary vascular resistance and pulmonary arterial pressure causing @entity8158 ( @entity8158 ) and RV failure. The pathology of PAH involves @entity455 remodeling including @entity358 and pulmonary arterial smooth muscle cell (PASMC) proliferation. Current therapies are limited to reverse the vascular remodeling. Investigating a key molecule is required for development of new therapeutic intervention. @entity52366 ( @entity52366 ) is a ubiquitous G-actin sequestering protein with diverse biological function and promotes wound healing and modulates inflammatory responses. However, it remains unknown whether @entity52366 has any protective role in @entity120 . The purpose of this study is to evaluate the whether @entity52366 can be used as a vascular-protective agent. In @entity6560 (MCT)-induced @entity120 @entity19 model, we showed that @entity19 treated with @entity52366 significantly attenuated the systolic pressure and @entity8158 , compared to the MCT treated @entity19 . Our data revealed for the first time that @entity52366 selectively targets Notch3-Col 3A- @entity1612 gene axis in preventing MCT-induced @entity120 and @entity8158 . Our study may provide pre-clinical evidence for @entity52366 and may consider as vasculo-protective agent for the treatment of @entity120 induced @entity8158 .

title: Thymosin Beta 4 protects @entity19 from @entity6560 -induced @entity120 and XXXX .

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular cell', 'vascular disease']

entities_list: @entity6560 :: ('MESH:D016686', 'Chemical') :: ['monocrotaline']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['Pulmonary hypertension', 'PH']

entities_list: @entity8158 :: ('MESH:D017380', 'Disease') :: ['right ventricular hypertrophy', 'RVH']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary arterial endothelial cell (PAEC) dysfunction']

answer: @entity8158 :: (MESH:D017380,Disease) :: ['right ventricular hypertrophy']


abstract: Little is known about the degree of disability and quality of life of @entity1 after major @entity130 . We conducted a prospective study to examine the incidence and predictors of functional limitation (FL). Between January 1, 1990 and March 30, 1990, 61 eligible @entity130 @entity1 were enrolled in the study (admission GCS score > or = 12, LOS > 24 hours). Functional limitation after @entity130 was measured at discharge and 3 months after discharge using the Quality of Well-being (QWB) scale, a more sensitive index to the well end of the functioning continuum (range, 0 = death to 1.000 = optimum functioning). Functional limitation was also measured using a standard ADL scale (range, 17 = full function to 41 = maximum dysfunction). Risk factors measured were injury severity, body region, @entity308 (CES-D) scale, and social support. Follow-up was achieved in 42 @entity1 (70%). The mean age was 30 years, 74% were male, 52% white, 41% hispanic, and 3% other. The mean ISS was 15, with 69% @entity1913 and a mean LOS of 12 days. The QWB scores improved between discharge and follow-up; discharge mean = 0.457 (+/- 0.048), follow-up mean = 0.613 (+/- 0.118), but the mean QWB score at follow-up still reflected a significant degree of functional limitation. The mean percentage of change in QWB scores was 34.5% (+/- 25.5%) with a range of -6.34% to 103.8%. The discharge mean FDS was 29 (+/- 6.2) while the follow-up FDS mean was 17 (+/- 3.8), reflecting that most @entity1 at follow-up reported near-perfect ADL functioning.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Functional limitation after major XXXX : a more sensitive assessment using the Quality of Well-being scale--the @entity130 recovery pilot project.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1913 :: ('MESH:D014949', 'Disease') :: ['blunt injuries']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

answer: @entity130 :: (MESH:D014947,Disease) :: ['trauma']